期刊文献+
共找到560篇文章
< 1 2 28 >
每页显示 20 50 100
Protein Profile of Human Lung Squamous Carcinoma Cell Line NCI-H226 被引量:2
1
作者 HAO ZHANG NA LI +5 位作者 YUE CHEN LING-YUN HUANG YI-CHING WANG GANG FANG DA-CHENG HE XUE-YUAN XIAO 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2007年第1期24-32,共9页
Objective To construct a database of human lung squamous carcinoma cell line NCI-H226 and to facilitate discovery of novel subtypes markers of lung cancer. Method Proteomic technique was used to analyze human lung squ... Objective To construct a database of human lung squamous carcinoma cell line NCI-H226 and to facilitate discovery of novel subtypes markers of lung cancer. Method Proteomic technique was used to analyze human lung squamous carcinoma cell line NCI-H226. The proteins of the NCI-H226 cells were separated by two-dimensional gel electrophoresis and identified by mass spectrometry. Results The results showed that a good reproducibility of the 2-D gel pattern was attained. The position deviation of matched spots among three 2-D gels was 1.95±0.53 mm in the isoelectric focusing direction, and 1.73±0.45 mm in the sodium dodecyl sulfate-polyacrylamide gel electrophoresis direction. One hundred and twenty-seven proteins, including enzymes, signal transduction proteins, structure proteins, transport proteins, etc. were characterized, of which, 29 identified proteins in NCI-H226 cells were reported for the first time to be involved in lung cancer carcinogenesis. Conclusion The information obtained from this study could provide some valuable clues for further study on the carcinogenetic mechanism of different types of lung cancer, and may help us to discover some potential subtype-specific biomarkers of lung cancer. 展开更多
关键词 lung squamous carcinoma nci-h226 cell line PROTEOMICS Two-dimensional datapase
下载PDF
Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer:A phase II open-label clinical study 被引量:9
2
作者 Shanshan Qin Hui Yu +10 位作者 Xianghua Wu Zhiguo Luo Huijie Wang Si Sun Mingzhu Huang Jia Jin Zhonghua Tao Jie Qiao Yu Feng Jialei Wang Jianhua Chang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2019年第2期339-348,共10页
Objective: The aim of this trial was to compare both the efficacy and the safety of a weekly nanoparticle albumin-bound paclitaxel(nab-paclitaxel) plus cisplatin vs. gemcitabine plus cisplatin in patients with advance... Objective: The aim of this trial was to compare both the efficacy and the safety of a weekly nanoparticle albumin-bound paclitaxel(nab-paclitaxel) plus cisplatin vs. gemcitabine plus cisplatin in patients with advanced non-small-cell lung cancer(NSCLC).Methods: A total of 84 participants received either 100 mg/m^2 nab-paclitaxel each week on d 1, 8 and 15 of a 28 day cycle, as well as cisplatin 75 mg/m^2 on d 1 every three weeks(nab-TP arm); or gemcitabine 1,000 mg/m^2 on d 1 and 8, plus cisplatin 75 mg/m^2 on d 1 every three weeks(GP arm). The primary end point was progression-free survival(PFS). The secondary end points were overall response rate(ORR) and overall survival(OS).Results: According to our analysis, the median PFS was 4.8 months for the nab-TP arm vs. 5.2 months for the GP arm(P=0.55). Analysis showed the median OS was 14.6 months for participants who were in the nab-TP arm vs. 15.1 months for those in the GP arm(P=0.94). Besides, nab-TP showed OS advantages over GP in patients harboring epidermal growth factor receptor(EGFR) mutation(26.7 vs. 15.3 months, P=0.046) and patients with a performance status of 0(23.5 vs. 14.7 months, P=0.020). It was found that incidences of drug-related grade 3 or 4 toxicities were comparable between the two treatment arms.Conclusions: Therefore, it can be seen that weekly nab-TP treatment has a similar efficacy and tolerability to GP treatment for patients who are undergoing their first-line treatment for NSCLC. It could be that survival differences among platinum doublets in the context of both EGFR mutation and performance status have the potential to be the basis for our further clinical trials. 展开更多
关键词 Albumin-bound paclitaxel CISPLATIN GEMCITABINE FIRST-line therapy ADVANCED non-small-cell lung cancer
下载PDF
Alterations and Its Mechanisms of Wnt Signal Pathway in Human High-matastatatic Large Cell Lung Cancer Cell Line L9981 by Transfecting with Nm23-H1 Gene 被引量:1
3
作者 Junke FU Zhe WANG +7 位作者 Sen WEI Gang CHEN Zhigang LI Jun CHEN Hongyu LIU Zhihao WU Ke XU Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期477-479,共3页
Backgroud and Objective Tumor metastasis is not only the malignant marker and characteristics of lung cancer, but also the main cause of failure to cure and lose their life of the
关键词 肺癌 扩散 临床 化疗
下载PDF
Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer 被引量:1
4
作者 Yongmei Yin Yiting Geng Xiaodong Li Xiaoli Hu Xiaofeng Chen Wei Li Yongqian Shu 《Journal of Nanjing Medical University》 2009年第6期392-397,共6页
Objective: To assess the efficacy and toxicity of gefitinib as a single agent treatment in Chinese patients with advanced non-small cell lung cancer (NSCLC). Methods: Forty-five patients with advanced NSCLC were t... Objective: To assess the efficacy and toxicity of gefitinib as a single agent treatment in Chinese patients with advanced non-small cell lung cancer (NSCLC). Methods: Forty-five patients with advanced NSCLC were treated with gefitinib at 250 mg daily until the disease progressed or the patient could not tolerate the toxicity. Results: None of the patients achieved a complete response (CR), while 15 patients achieved a partial remission (PR) and 17 experienced a stable disease (SD). Thirteen patients continued to have a progressive disease (PD). The response rate and the disease control rate were 33.3% and 71.1%, respectively. The symptom remission rate was 72.5%, and the median remission time was 8 days. The median survival time was 15.3 months. The median progression-free survival time was 6.0 months. The most common toxicities included rash (53.3%) and diarrhea (33.3%). Dehydration and pruritus of the skin developed in 26.7% and 22.2% of the patients, respectively. Hepatic toxicity occurred in 6.7% of patients and oral ulceration occurred in 4.4% of patients. Conclusion: Single agent treatment with gefitinib is effective against advanced NSCLC, and is well tolerated in Chinese patients. 展开更多
关键词 GEFITINIB non-small cell lung cancer (NSCLC) first-line treatment
下载PDF
Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer:a report of 6 cases
5
作者 Fang Wang Liangping Xia +4 位作者 Guifang Guo Huijuan Qiu Feifei Zhou Bei Zhang Li Zhang 《The Chinese-German Journal of Clinical Oncology》 CAS 2010年第9期502-506,共5页
Objective:Cetuximab combined with chemotherapy has been used to treat non-small cell lung cancer (NSCLC) in recent years, most of them were first line setting.This study was to summarize our experiences in treating NS... Objective:Cetuximab combined with chemotherapy has been used to treat non-small cell lung cancer (NSCLC) in recent years, most of them were first line setting.This study was to summarize our experiences in treating NSCLC patients with cetuximab in the non-first line setting.Methods:From October 1st 2006 to December 31st 2009, six NSCLC patients were treated with cetuximab combined standard chemotherapy as non-first line setting in Sun Yat-sen University Cancer Center, China.The short-term efficacies and safeties were analyzed.Results:1.A total of 18 cycles of cetuximab treatment, with a median of two cycles in the whole group.2.There were 6 patients treated as non-first line setting, overall response rate (ORR) was 33.3% (2/6), disease control rate (DCR) was 33.3% (2/6), median time to progression (TTP) was 3.5 (3-4) months, and median OS was 18 (4-28) months.3.There were 50% (3/6) patients occurred acne-like rash within three weeks, their ORR was 66.7% (2/3), and DCR was 66.7% (2/3), however, both of ORR and DCR in patients who didn't occurred acne-like rash were 0% (0/3), the differences of ORR, DCR between two groups were in significant different (P=0.143).4.There was no treatment-associated death and no cetuximab-associated discontinuation.The incidence of acne-like rash was 50% occurred within three weeks, there were two patients suffered side effects associated with chemotherapy.Conclusion:The data of cetuximab application in non-first line setting for patients with NSCLC were rare, and the addition of cetuximab in those population was safe. 展开更多
关键词 CETUXIMAB non-small cell lung cancer (NSCLC) efficacy safety non-first line
下载PDF
The Expression Levels of KAI1 Gene and Its Mechanism in Human Lung Cancer Cell Lines
6
作者 Ying ZHAO Yu FAN Li MA Jun CHEN Sen WEI Zhigang LI Hongyu LIU Haisu WAN Zhihao WU Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期499-501,共3页
Background and Objective Lung cancer is one of the most malignant cancers which is hazarding the people’s health and life in the world. In the past half century, the incidence and mortality
关键词 肺癌 临床 诊断 治疗
下载PDF
Screening and Verifying of Metastasis-associated Genes of Human Lung Cancer Cell Lines with Different Metastatic Potential
7
作者 Shanxian GUO Yu FAN Li MA Jun CHEN Sen WEI Zhigang LI Hongyu LIU Haisu WAN Zhihao WU Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期507-508,共2页
Background and Objective Lung cancer is the most lethal malignangy that threatens human health and lives nowadays in the world, The overall cure rate of lung cancer is only 13% -15%,
关键词 肺癌 诊断 治疗 医学
下载PDF
The Difference of the Copy Number Variation and Loss of Heterozygosity of Human Lung Large Cell Cancer Cell Line with Different Metastatic Potential
8
作者 Bin HU Xiaoming QIU Ting WANG Yu FAN Li MA Jun CHEN Sen WEI Zhigang LI Hongyu LIU Haisu WAN Zhihao WU Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期512-514,共3页
Background and Objective It has been proven that copy number gain/or loss (copy number variation CNV) in uences gene expression and result in phenotypic variation by
关键词 肺癌 癌细胞 CNV 治疗 疗效
下载PDF
Alterations in the Cytoskeleton and Biological Behavior in Human Lung Cancer Cell Line L9981 by Nm23-H1 gene Transfection
9
作者 Zhe WANG Junke FU +4 位作者 Zhihao WU Hongyu LIU Jun CHEN Liya SUN Q inghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期475-476,共2页
Objective and Methods The key cause of failure to cure and high mortality in lung cancer. At present, it has been known
关键词 肺癌 治疗 诊断 疗效
下载PDF
Effects of Methylseleninic Acid on the Proliferation and Cell Cycle in Human High Metastatic Large Cell Lung Cancer Cell Line L9981 and Its Molecular Mechanism
10
作者 Xiaorong ZHONG Yu FAN Li MA Jun CHEN Sen WEI Zhigang LI Hongyu LIU Haisu WAN Zhihao WU Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期498-499,共2页
Background and Objective Lung cancer is the rst killer of human being in the whole world. Recently, although many treatment strategies have been developed, the anti-cancer effects
关键词 肺癌 临床 治疗 疗效
下载PDF
Safety and Efficacy of Racotumomab-Alum Vaccine as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer
11
作者 Eduardo Santiesteban Leslie Perez +10 位作者 Sailyn Alfonso Elia Neninger Soraida Acosta Yoana Flores Maurenis Hernandez Carmen Viada Robin García Meylán Cepeda Daymys Estevez Yoisbel Moreno Amparo Macías 《International Journal of Clinical Medicine》 2014年第14期844-850,共7页
Despite extensive clinical research in non-small cell lung cancer (NSCLC), overall survival is still poor. Racotumomab-alum is an anti-idiotypic cancer vaccine that targets NeuGcGM3 tumor associated ganglioside. The a... Despite extensive clinical research in non-small cell lung cancer (NSCLC), overall survival is still poor. Racotumomab-alum is an anti-idiotypic cancer vaccine that targets NeuGcGM3 tumor associated ganglioside. The aim of this study was to evaluate safety and efficacy of racotumomab-alum in advanced NSCLC patients with progressive disease. This expanded access program included 86 histologically confirmed NSCLC patients, 18 years or older age, with advanced disease and without therapeutic option, with ECOG performance status ≤3, adequate organ functions and signed informed consent. The primary endpoint was overall survival and toxicity was measure assessed treatment-related toxicity according CTCAEv3. The study was approved by ethical review boards of participant institutions. Racotumomab-alum treatment consisted in 5 biweekly intradermal doses (1 mg/mL) during the induction phase of treatment (2 months). The maintenance phase consisted in monthly re-immunizations until unacceptable toxicity or PS worsening. The median overall survival time of all patients treated with racotumomab-alum was 8.96 months. The survival rates at 12 and 24 months were 42.8% and 28.0%, respectively. Patients that completed the induction phase of treatment (five doses or more) reached a median OS of 12.1 months. The most common adverse events were injection site reaction, bone pain, cough and asthenia. Racotumomab-alum cancer vaccine could be considered an effective and safe treatment option as second-line therapy for advanced NSCLC. Further clinical studies should be conducted to confirm this result. 展开更多
关键词 NON-SMALL cell lung cancer cancer VACCINE SECOND-line Treatment
下载PDF
Influence of Nm23-H1 Gene Site Mutagenesis on Invasive And Metastatic Phenotype in Human High-Metastatic Large Cell Lung Cancer Cell Line L9981
12
作者 Daxing ZHU Bin HU Xiaomin Q IU Ting WANG Yu FAN Li MA Jun CHEN Sen WEI Zhigang LI Hongyu LIU Haisu WAN Zhihao WU Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期515-517,共3页
Background and Objective Invasion and metastasis is not only the malignant phenotypes of lung cancer but also the main cause of death. To study and elucidate the molecular mechanism
关键词 NM23-H1 肺癌 治疗 疗效
下载PDF
INFLUENCE OF ZINC,MANGANESE AND SELENIUM ONSUPEROXIDE DISMUTASE ACTIVITY IN LUNGCANCER TISSUE AND CELL IN CULTURE 被引量:1
13
作者 喻伦银 夏东 刘汉桥 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 1996年第1期42-45,共4页
In this experiment,the cancer tissues and cells,Which were derived from Lewis lung cancer and A549 lung Cancer cell line,were respectively divided into four groups and zinc, manganese and selenium were respectively ad... In this experiment,the cancer tissues and cells,Which were derived from Lewis lung cancer and A549 lung Cancer cell line,were respectively divided into four groups and zinc, manganese and selenium were respectively added to the medium for 24 hours. The superoxide dismutase activity in the tissues and the cells was estimated. It was found that the SOD activity was enhanced by zinc and manganese and the effect of zinc on SOD activity was superior to that of manganese. We supposed that the enhance of the SOD activity was relative to the activation of the SOD apoenzymes. This experimental result indicated that the inhibitory effect of zinc and manganese on carcinogenesis was achieved by SOD and the elements might be considered a SOD activator. 展开更多
关键词 Superoxide dismutase ZINC Manganese Selenium lung cancer TISSUE cell line Culture.
下载PDF
The pooled analysis of single gemcitabine for non-small cell lung cancer patients with elderly age 被引量:1
14
作者 Fang Wang Liangping Xia +3 位作者 Guifang Guo Huijuan Qiu Feifei Zhou Wenzhuo He 《The Chinese-German Journal of Clinical Oncology》 CAS 2010年第12期683-687,共5页
Objective:Gemcitabine,used as single agent for elderly patients with non-small cell lung cancer (NSCLC),was demonstrated effective in this population based on phase II studies.The aim of this study was to summarize al... Objective:Gemcitabine,used as single agent for elderly patients with non-small cell lung cancer (NSCLC),was demonstrated effective in this population based on phase II studies.The aim of this study was to summarize all those phase II studies with the hope to get a comprehensive understanding of gemcitabine efficacy.Methods:The PubMed database was used to search all the papers on NSCLC associated with gemcitabine used as single agent in the first line setting till to March 31st,2010.And the medians and their 95% CI of overall response rate (ORR),disease control rate (DCR),progression free survival (PFS),and overall survival (OS) were calculated.Results:1.There were 7 papers including 410 patients with performance status (PS) ≤ 2 and advanced stage collected.2.The dose-intensities of gemcitabine were 843.75 mg/m 2 /week-1125 mg/m 2 /week in the 4-week schedule,and 666.7 mg/m 2 /week in the 3-week schedule.3.The median age was 73.8 (95% CI was 72.44,75.16) years old;36.1% (95% CI:31.4%,40.7%) of patients with stage IIIB and 60.5% (95% CI:55.8%,65.2%) of patients with stage IV;35.9% (95% CI:31.2%,40.5%) patients were adenocarcinomas and 43.7% (95% CI:38.9%,48.5%) patients were squamous cell carcinomas (SCCs).4.The ORR,DCR,PFS/TTP,and OS were 22.3% (95% CI:18.2%,26.5%),58.4% (95% CI:53.5%,63.4%),3.6 (95% CI:2.9,5.15) months and 6.68 (95% CI:5.4,8.11) months,respectively.Conclusion:Gemcitabine as single agent applied in this special population was effective and can be well tolerated under different doses and usage. 展开更多
关键词 ELDERLY non-small cell lung cancer (NSCLC) pooled-analysis GEMCITABINE first line setting
下载PDF
Effects of chimeric intron on the epithelial-mesenchymal transformation of non-small cell lung cancer PC-9
15
作者 Liang Liao Guo-Hui Yang 《Journal of Hainan Medical University》 2021年第2期1-5,共5页
Objective:To investigate the effects of Intron on the EMT capability of non-small cell lung cancer cell line PC-9.Methods:Firstly,using the psiCHECK-2 plasmid as a basic framework to construct the recombinant plasmid ... Objective:To investigate the effects of Intron on the EMT capability of non-small cell lung cancer cell line PC-9.Methods:Firstly,using the psiCHECK-2 plasmid as a basic framework to construct the recombinant plasmid of psiCHECK-2-Intron dual-luciferase reporter gene;secondly,the psiCHECK-2-Intron and psiCHECK-2 were transfected into PC-9 cells respectively.The migration and invasion abilities of PC-9 cells were analyzed by Matrigel assay.The expression changes of EMT related hallmarks,including N-cadherin,β-catenin and snail,were detected by qRT-PCR and Western Blotting.Results:Compared with the control group,the migration and invasion abilities of PC-9 cells in Intron group significantly decreased(p<0.001).The expression of N-cadherin,β-catenin and snail also down-regulated(p<0.001).Conclusion:The introns could inhibit the EMT of PC-9 cells. 展开更多
关键词 Chimeric intron PC-9 cell line Dual-fluorescent protein reporter gene Non-small cell lung cancer(NSCLC) Epithelial-mesenchymal transformation(EMT)
下载PDF
Transfection of Nm23-H1 Gene Inhibited the Metastatic Potential of Human High-metastatic Large Cell Lung Cancer L9981
16
作者 Haixia ZHENG Zhilin SUN +10 位作者 Yang QIN Wen ZHU Li REN Jun CHEN Sen WEI Zhigang LI Hongyu LIU Haisu WAN Zhihao WU Ke XU Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期490-492,共3页
Background and objective Invasion and metastasis is not only the malignant phenotypes of lung cancer but also the main cause of death. Elucidating the molecular mechanism of
关键词 NM23-H1 肺癌 临床 治疗
下载PDF
志苓胶囊对人小细胞肺癌细胞系NCI-H446增殖抑制和诱导凋亡的影响 被引量:7
17
作者 陈英玉 潘云苓 +3 位作者 刘庭波 潘明继 胡辉亮 胡建达 《中国中西医结合杂志》 CAS CSCD 北大核心 2007年第6期531-534,共4页
目的研究志苓胶囊(ZLJN)对人小细胞肺癌细胞系NCI-H446增殖影响及诱导凋亡作用。方法将志苓胶囊按其不同的中西药成分配制成不同浓度的中药组、西药组和复方组,与NCI-H446共培养后,采用MTT比色法、集落形成试验,分别检测细胞存活率和集... 目的研究志苓胶囊(ZLJN)对人小细胞肺癌细胞系NCI-H446增殖影响及诱导凋亡作用。方法将志苓胶囊按其不同的中西药成分配制成不同浓度的中药组、西药组和复方组,与NCI-H446共培养后,采用MTT比色法、集落形成试验,分别检测细胞存活率和集落形成率。通过流式细胞仪进行DNA倍体分析、Bcl-2蛋白表达、线粒体跨膜电位及Caspase-3活性检测;DNA片段化分析法、Annexin V-FITC标记法、TdT酶介导的原位缺口末端标记法(TUNEL)检测凋亡细胞。结果不同浓度的药物组与NCI-H446共培养后,细胞生长明显受抑制,细胞集落形成率明显降低,呈浓度依赖性;各药物组处理后的细胞线粒体跨膜电位和Bcl-2蛋白表达水平下降,Caspase-3活性增强;琼脂糖凝胶电泳可见典型的DNA梯形带;各药物组均检测到明显的亚二倍体G1峰(凋亡峰);Annexin V-FITC法检测到早期凋亡细胞;TUNEL法检测到晚期凋亡细胞。复方组诱导细胞凋亡作用强于中药组和西药组。结论志苓胶囊可以有效抑制NCI-H446细胞增殖,诱导其凋亡,细胞线粒体跨膜电位水平降低,Caspase-3活性增强和Bcl-2表达下调可能参与了该过程。 展开更多
关键词 小细胞肺癌细胞系nci-h446 志苓胶囊 增殖 凋亡
下载PDF
志苓胶囊对小细胞肺癌细胞株NCI-H446细胞凋亡及h-TERT、CD44表达的影响 被引量:4
18
作者 陈英玉 潘云苓 +3 位作者 郑志宏 潘明继 胡建达 刘庭波 《中国药理学通报》 CAS CSCD 北大核心 2008年第10期1382-1386,共5页
目的研究志苓胶囊(抗癌复方Ⅱ号)对人小细胞肺癌细胞株NCI-H446诱导凋亡作用机制以及对细胞黏附分子表达的影响。方法将志苓胶囊按其不同的中西药成份配制成相应的中药组、西药组和复方组,与NCI-H446共培养后,倒置显微镜观察、Hochest33... 目的研究志苓胶囊(抗癌复方Ⅱ号)对人小细胞肺癌细胞株NCI-H446诱导凋亡作用机制以及对细胞黏附分子表达的影响。方法将志苓胶囊按其不同的中西药成份配制成相应的中药组、西药组和复方组,与NCI-H446共培养后,倒置显微镜观察、Hochest33258荧光染色法检测凋亡细胞,RT-PCR、Western blot、流式细胞仪分别检测bcl-2、bax、hTERT基因mRNA和相应蛋白表达水平变化以及黏附分子CD44的表达变化。结果NCI-H446经不同的药物组处理后,倒置显微镜、Hochest33258荧光染色可观察到细胞凋亡形态学改变,bcl-2基因mRNA和蛋白表达水平均有不同程度下降,bax基因表达水平则有不同程度增强,复方组改变最明显,各药物组与对照组比较差异具有显著性(P<0.01)。中药组和西药组hTERT基因和蛋白表达水平未见明显改变,复方组表达水平下调,与对照组比较差异具有显著性(P<0.01)。各药物组CD44表达水平降低,其中复方组降低水平最明显(P<0.01)。结论志苓胶囊可能通过下调NCI-H446细胞bcl-2、hTERT基因和CD44分子表达,增强bax基因表达,从而诱导NCI-H446细胞凋亡,抑制细胞黏附、转移。 展开更多
关键词 小细胞肺癌细胞株nci-h446 志苓胶囊 凋亡 HTERT CD44
下载PDF
小白菊内酯对人小细胞肺癌NCI-H446细胞增殖及凋亡作用研究 被引量:3
19
作者 刘捷 徐玲 《重庆医科大学学报》 CAS CSCD 北大核心 2018年第3期414-419,共6页
目的:研究小白菊内酯(parthenolide,PTL)对人小细胞肺癌(small cell lung cancer,SCLC)细胞株NCI-H446增殖及凋亡作用的影响及其可能的分子机制。方法:NCI-H446细胞株由武汉大学细胞库提供,PTL购于Gene Operation公司,将NCIH446细胞株... 目的:研究小白菊内酯(parthenolide,PTL)对人小细胞肺癌(small cell lung cancer,SCLC)细胞株NCI-H446增殖及凋亡作用的影响及其可能的分子机制。方法:NCI-H446细胞株由武汉大学细胞库提供,PTL购于Gene Operation公司,将NCIH446细胞株分为对照组和实验组(1.5μg/m L组、2.0μg/m L组、2.5μg/m L组和3.0μg/m L组),向实验组细胞培养基中加入对应浓度PTL处理细胞,对照组中加入等体积无血清培养基。MTT比色法观测不同浓度PTL对NCI-H446细胞增殖的影响;Hochest 33258染色后,荧光显微镜下观察细胞核形态学变化;流式细胞术(flow cytometry,FCM)分析细胞凋亡率;RT-PCR分别检测不同浓度组PTL处理48 h后细胞中NF-κB、Caspase-3、Caspase-8、Caspase-9基因的表达状态,Wsetern blot检测NF-κB、Caspase-3、Caspase-8、Caspase-9蛋白的表达状态。结果:PTL抑制小细胞肺癌NCI-H446细胞增殖并呈浓度依赖性;Hochest33258染色结果显示,PTL作用NCI-H446细胞48 h后,细胞数量减少,细胞核固缩碎裂,形成凋亡小体,导致细胞凋亡;流式细胞术检测显示,PTL处理NCI-H446细胞后,细胞凋亡率与药物浓度梯度呈浓度依赖性,差异有统计学意义(P<0.05);RT-PCR及Wsetern blot结果显示,与对照组比较,经PTL处理的NCI-H446细胞中NF-κB m RNA及蛋白表达下调,同时Caspase-3、Caspase-8、Caspase-9 m RNA及蛋白表达上调,差异具有统计学意义(P<0.05)。结论:PTL能抑制NCI-H446细胞的增殖并诱导其发生凋亡,PTL的作用机制可能与抑制NF-κB信号通路及活化Caspase系统有关。 展开更多
关键词 小白菊内酯 小细胞肺癌HCI-H446 细胞增殖 细胞凋亡
下载PDF
人肺癌NCI-H446细胞生成肿瘤干细胞球 被引量:2
20
作者 乐涵波 刘晓光 曾芳 《解剖学报》 CAS CSCD 北大核心 2012年第4期500-505,共6页
目的探索人肺癌NCI-H446细胞系干细胞球体的培养,并鉴定其生物学特性。方法用无血清培养基培养人肺癌NCI-H446细胞得到肿瘤细胞球。将肿瘤细胞球传代扩增,并用含血清培养基培养促使其分化;四甲基偶氮唑盐(MTT)比色检测肿瘤球和普通NCI-H... 目的探索人肺癌NCI-H446细胞系干细胞球体的培养,并鉴定其生物学特性。方法用无血清培养基培养人肺癌NCI-H446细胞得到肿瘤细胞球。将肿瘤细胞球传代扩增,并用含血清培养基培养促使其分化;四甲基偶氮唑盐(MTT)比色检测肿瘤球和普通NCI-H446细胞的增殖能力,并将肿瘤球和普通NCI-H446细胞分别植入裸鼠皮下,观察肿瘤形成;Transwell侵袭实验检测肿瘤球和普通NCI-H446细胞的侵袭能力的不同;流式细胞术检测CD133、CD44在肿瘤球和普通NCI-H446细胞中的表达,并筛选细胞表面标志物。结果在无血清培养基中,人肺癌NCI-H446细胞可以形成少量的肿瘤细胞球,并显示很强的自我更新和增殖能力,在含血清环境中能够诱导肿瘤球分化而贴壁生长;在动物实验中,接种5×105个细胞时,肿瘤球细胞较普通NCI-H446细胞显示更强的致瘤能力;在侵袭实验中,肿瘤球细胞的侵袭能力高于普通NCI-H446细胞;干细胞标志物CD133及CD44在肿瘤球细胞的表达较普通NCI-H446细胞明显增高。结论人肺癌细胞NCI-H446中存在癌干细胞,且可以通过无血清培养、分离和富集。 展开更多
关键词 肺癌 nci-h446细胞系 无血清培养 癌干细胞 细胞表面标志 流式细胞术
下载PDF
上一页 1 2 28 下一页 到第
使用帮助 返回顶部